BioMS Medical Corp.

BioMS Medical is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies.

BioMS Medical has obtained an exclusive worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, dirucotide, is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment.

Read more: